Muralidhar is one of the key founding members of Clonz.
His past expertise in development of biosimilar monoclonal antibodies is one of the core strengths of the company and he is playing an instrumental role in co-ordinating the various product development activities of Clonz.
Muralidhar’s experience along with the team of early scientists at a reputed pharmaceutical company during the development of the world’s first therapeutic biosimilar monoclonal antibody, is a major strength. His expertise also contributed to other biotech companies to gain the momentum in development of biosimilars. His innovative thinking and speed filled with commercial elements is a boon to the company.
Contact Murali at: muralidhar.mamilla@clonzbio.com
Clonz biotech was founded in 2010 by an experienced team of recognized leaders in biosimilar research and manufacturing.